Advanced Tech, Crossover Investors Drive Biopharma IPO Surge
"After 15 US venture-backed life-sciences initial public offerings roared out of the gate in the third quarter, another crop looks poised to close out the year on a high note. The pace is set to continue this week with stock market debuts by PhaseBio Pharmaceuticals, LogicBio Therapeutics and SI-BONE. And just last week in its offering, liquid biopsy startup Guardant Health was valued at about $1.59 billion."
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.